Dr. Devendra Kc, MD
Medical Oncology (Medical Oncology Physician)
Hartford Hospital Cvo Provider Enrollment, 80 Seymour Street
Hartford, CT 06102
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 322
Licensed in Colorado since 2012, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CT license 64971 (first issued 2020; active) -
Hospitalist Physician
TX license R1972 (first issued 2017; canc non-renewal) -
Internal Medicine Physician
CO license 51460 (first issued 2012; expired) · TX license R1972 (first issued 2017; canc non-renewal)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hartford Hospital Hartford, CT
- The Hospital of Central Connecticut New Britain, CT
- Middlesex Hospital Middletown, CT
- William W Backus Hospital Norwich, CT
Medical groups
- Hartford Hospital (1,044 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 322
- Services billed
- 989
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 426 | 118 |
| Established patient office or other outpatient visit, 20-29 minutes | 198 | 108 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 89 | 21 |
| Established patient office or other outpatient visit, 40-54 minutes | 89 | 34 |
| New patient office or other outpatient visit, 45-59 minutes | 54 | 54 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 22 | 21 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Hartford, CT | 155 |
| Revlimid (lenalidomide) | 123 |
| Eliquis (apixaban) Other prescribers in Hartford, CT | 115 |
| Hydroxyurea Other prescribers in Hartford, CT | 87 |
| Prednisone Other prescribers in Hartford, CT | 64 |
| Dexamethasone Other prescribers in Hartford, CT | 59 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Hartford, CT | 57 |
| Allopurinol Other prescribers in Hartford, CT | 46 |
| Calquence (acalabrutinib maleate) | 45 |
| Lenalidomide | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $169,896 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low…
Celgene Corporation - A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermedi…
E.r. Squibb & Sons, L.l.c. - ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05949684
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.